Non-small cell lung carcinoma - Revision history

Michael at 17:01, 18 June 2017

2017-06-18T17:01:12Z

← Older revision		Revision as of 17:01, 18 June 2017
Line 39:		Line 39:
	In the clinical context, it is often referred to as '''non-small cell lung cancer'''; this ignores the fact that not all non-small cell lung cancer fits into the [[carcinoma]] category.		In the clinical context, it is often referred to as '''non-small cell lung cancer'''; this ignores the fact that not all non-small cell lung cancer fits into the [[carcinoma]] category.

	''Poorly differentiated carcinoma of the lung'', ''non-small cell ~~carcinma~~'' and ''poorly differentiated lung carcinoma'' redirect to this article.		''Poorly differentiated carcinoma of the lung'', ''non-small cell carcinoma'' and ''poorly differentiated lung carcinoma'' redirect to this article.

	==General==		==General==

2017-06-18T17:01:03Z

← Older revision		Revision as of 17:01, 18 June 2017
Line 39:		Line 39:
	In the clinical context, it is often referred to as '''non-small cell lung cancer'''; this ignores the fact that not all non-small cell lung cancer fits into the [[carcinoma]] category.		In the clinical context, it is often referred to as '''non-small cell lung cancer'''; this ignores the fact that not all non-small cell lung cancer fits into the [[carcinoma]] category.

	''Poorly differentiated carcinoma of the lung'' and ''poorly differentiated lung carcinoma'' redirect to this article.		''Poorly differentiated carcinoma of the lung'', ''non-small cell carcinma'' and ''poorly differentiated lung carcinoma'' redirect to this article.

	==General==		==General==

2016-12-20T17:21:51Z

← Older revision		Revision as of 17:21, 20 December 2016
Line 122:		Line 122:
	\|-		\|-
	\| Non-small cell carcinoma, favour adenocarcinoma		\| Non-small cell carcinoma, favour adenocarcinoma
	\| TTF-1 or napsin +ve		\| [[TTF-1]] or napsin +ve
	\|-		\|-
	\| Non-small cell carcinoma, favour squamous cell carcinoma		\| Non-small cell carcinoma, favour squamous cell carcinoma
	\| p40 or p63 +ve		\| [[p40]] or [[p63]] +ve
	\|-		\|-
	\| Non-small cell carcinoma-not otherwise specified		\| Non-small cell carcinoma-not otherwise specified

2016-06-06T17:33:34Z

IHC

← Older revision		Revision as of 17:33, 6 June 2016
Line 89:		Line 89:

	Note:		Note:
	*~~Immunostains~~ should ~~not~~ favour adenocarcinoma or squamous cell carcinoma - see ''Sloan-Kettering algorithm'' below.		*If immunostains favour adenocarcinoma or squamous cell carcinoma, the case should be sign as ''favour adenocarcinoma'' or ''favour squamous cell carcinoma'', see ''Sloan-Kettering algorithm'' below and ''Sign out'' section.

	===Adenocarcinoma versus squamous carcinoma===		===Adenocarcinoma versus squamous carcinoma===

2016-05-16T14:35:25Z

Grading

← Older revision		Revision as of 14:35, 16 May 2016
Line 69:		Line 69:

	===Grading===		===Grading===
	*NSCC-NOS, NSCC-favour adenocarcinoma, NSCC-favour SCC are grade 4.		*''NSCC-NOS'', ''NSCC favour adenocarcinoma'', ''NSCC favour SCC'' are grade 4.

	Note:		Note:

2016-05-16T14:34:38Z

Grading

← Older revision		Revision as of 14:34, 16 May 2016
Line 69:		Line 69:

	===Grading===		===Grading===
	*NSCC-NOS is grade 4~~, as per the CAP protocol~~.		*NSCC-NOS, NSCC-favour adenocarcinoma, NSCC-favour SCC are grade 4.

	Note:		Note:

2016-05-16T14:31:29Z

Microscopic

← Older revision		Revision as of 14:31, 16 May 2016
Line 67:		Line 67:
	*[[Malignant melanoma]].		*[[Malignant melanoma]].
	*Other poorly differentiated neoplasms		*Other poorly differentiated neoplasms

			===Grading===
			*NSCC-NOS is grade 4, as per the CAP protocol.

			Note:
			*In a large series of patients, there is no statistical difference in survival been grade 3 and grade 4.<ref name=pmid16678584>{{Cite journal \| last1 = Sun \| first1 = Z. \| last2 = Aubry \| first2 = MC. \| last3 = Deschamps \| first3 = C. \| last4 = Marks \| first4 = RS. \| last5 = Okuno \| first5 = SH. \| last6 = Williams \| first6 = BA. \| last7 = Sugimura \| first7 = H. \| last8 = Pankratz \| first8 = VS. \| last9 = Yang \| first9 = P. \| title = Histologic grade is an independent prognostic factor for survival in non-small cell lung cancer: an analysis of 5018 hospital- and 712 population-based cases. \| journal = J Thorac Cardiovasc Surg \| volume = 131 \| issue = 5 \| pages = 1014-20 \| month = May \| year = 2006 \| doi = 10.1016/j.jtcvs.2005.12.057 \| PMID = 16678584 }}</ref>

	===Images===		===Images===

2016-05-16T14:10:01Z

← Older revision		Revision as of 14:10, 16 May 2016
Line 9:		Line 9:
	\| LMDDx = [[lung adenocarcinoma]], [[squamous cell carcinoma of the lung\|lung squamous carcinoma]], [[lung small cell carcinoma]], poorly differentiated metastatic [[carcinoma]], other poorly differentiated neoplasms		\| LMDDx = [[lung adenocarcinoma]], [[squamous cell carcinoma of the lung\|lung squamous carcinoma]], [[lung small cell carcinoma]], poorly differentiated metastatic [[carcinoma]], other poorly differentiated neoplasms
	\| Stains =		\| Stains =
	\| IHC = pankeratin +ve, [[CD56]] -ve, chromogranin A -ve, synaptophysin -ve, TTF-1 +ve/-ve, p63 +ve/-ve		\| IHC = pankeratin +ve, [[CD56]] -ve, chromogranin A -ve, synaptophysin -ve, [[TTF-1]] +ve/-ve, [[p63]] +ve/-ve
	\| EM =		\| EM =
	\| Molecular =		\| Molecular =

2016-05-04T03:36:31Z

← Older revision		Revision as of 03:36, 4 May 2016
Line 7:		Line 7:
	\| Micro =		\| Micro =
	\| Subtypes = NSCC favour adenocarcinoma, NSCC favour squamous cell carcinoma, NSCC-not otherwise specified		\| Subtypes = NSCC favour adenocarcinoma, NSCC favour squamous cell carcinoma, NSCC-not otherwise specified
	\| LMDDx = [[lung adenocarcinoma]], [[squamous cell carcinoma of the lung\|lung squamous carcinoma]], [[lung small cell carcinoma]], poorly differentiated metastatic [[carcinoma]]		\| LMDDx = [[lung adenocarcinoma]], [[squamous cell carcinoma of the lung\|lung squamous carcinoma]], [[lung small cell carcinoma]], poorly differentiated metastatic [[carcinoma]], other poorly differentiated neoplasms
	\| Stains =		\| Stains =
	\| IHC = pankeratin +ve, [[CD56]] -ve, chromogranin A -ve, synaptophysin -ve, TTF-1 +ve/-ve, p63 +ve/-ve		\| IHC = pankeratin +ve, [[CD56]] -ve, chromogranin A -ve, synaptophysin -ve, TTF-1 +ve/-ve, p63 +ve/-ve
Line 65:		Line 65:
	*Large cell variant of [[small cell carcinoma of the lung]].		*Large cell variant of [[small cell carcinoma of the lung]].
	*[[Lung metastasis]] - imaging suggestive of a metastasis or a history of malignancy.		*[[Lung metastasis]] - imaging suggestive of a metastasis or a history of malignancy.
			*[[Malignant melanoma]].
			*Other poorly differentiated neoplasms

	===Images===		===Images===

2016-04-29T14:44:40Z

Sign out

← Older revision		Revision as of 14:44, 29 April 2016
Line 123:		Line 123:
	\|}		\|}

			===Not otherwise specified===
	<pre>		<pre>
	Lung, Left Lower Lobe, Core Biopsy:		Lung, Left Lower Lobe, Core Biopsy:
Line 137:		Line 138:
	The neuroendocrine markers (chromogranin A, synaptophysin, CD56) and the squamous		The neuroendocrine markers (chromogranin A, synaptophysin, CD56) and the squamous
	markers (p63, CK5/6) are negative; thus, the tumour is not further classified.		markers (p63, CK5/6) are negative; thus, the tumour is not further classified.
			</pre>

			===Favour squamous===
			<pre>
			Lung, Left Upper Lobe, Core Biopsy:
			- NON-SMALL CELL CARCINOMA, favour squamous cell carcinoma, see comment.

			Comment:
			The tumour stains as follows:
			POSITIVE: AE1/AE3, CK5/6, CK7.
			NEGATIVE: TTF-1, napsin A, p63, CDX2, CK20, S-100.

			EGFR/ALK testing has been ordered.

			The immunostains favour squamous cell carcinoma.
	</pre>		</pre>